Metagenomi Therapeutics PE Ratio 2022-2026 | MGX

Current and historical p/e ratio for Metagenomi Therapeutics (MGX) from 2022 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Metagenomi Therapeutics PE ratio as of June 17, 2026 is 0.00.

Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Metagenomi Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2026-06-17 1.18 0.00
2026-03-31 1.34 $-2.29 0.00
2025-12-31 1.62 $-2.36 0.00
2025-09-30 2.37 $-2.14 0.00
2025-06-30 1.48 $-2.10 0.00
2025-03-31 1.36 $-1.85 0.00
2024-12-31 3.61 $-2.36 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.052B $0.025B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00